Intelligent Bio Solutions Inc. (INBS)
NASDAQ:INBS
Want to see INBS full AI Analyst Report?
Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▲(94.17% Upside)
Action:Reiterated
Date:06/17/26
The score is held down primarily by weak financial performance (large losses and persistent cash burn) and a negative technical trend (price below key moving averages with weak momentum). Corporate events provide some support via FDA study progress, but potential dilution risk and a loss-based valuation profile limit the upside in the overall score.
Positive Factors
Recurring consumables revenue
A business model deriving recurring revenue from single-use cartridges creates predictable, high-frequency demand tied to testing volume. Durable consumable sales can stabilize revenue streams, improve lifetime customer value and support gross-margin leverage as device penetration expands across workplaces and corrections.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow at a multi-million dollar annualized pace creates ongoing financing needs. Over several quarters this erodes liquidity, constrains ability to invest in sales and manufacturing scale, and increases reliance on external capital, raising long-term sustainability risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
A business model deriving recurring revenue from single-use cartridges creates predictable, high-frequency demand tied to testing volume. Durable consumable sales can stabilize revenue streams, improve lifetime customer value and support gross-margin leverage as device penetration expands across workplaces and corrections.
Read all positive factors
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.48M
Dividend YieldN/A
Average Volume (3M)151.23K
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth33.26%
EPS Growth49.65%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-12.52
Shares Outstanding2,391,846
10 Day Avg. Volume69,209
30 Day Avg. Volume151,230
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap-0.65
Enterprise Value/Revenue-0.91
Enterprise Value/Gross Profit-2.84
Enterprise Value/Ebitda0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Intelligent Bio Solutions Business Overview & Revenue Model
Company Description
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the S...
How the Company Makes Money
INBS primarily generates revenue by selling and/or leasing its fingerprint drug screening hardware (portable reader devices) and, more importantly, by selling recurring consumables (single-use test cartridges) used with the system. Additional reve...
Intelligent Bio Solutions Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.91M | 3.05M | 3.11M | 1.26M | 0.00 | 1.98M |
| Gross Profit | 1.26M | 1.25M | 1.43M | 326.67K | 0.00 | 1.98M |
| EBITDA | -7.72M | -9.45M | -9.05M | -9.47M | -8.33M | 0.00 |
| Net Income | -11.61M | -10.57M | -10.16M | -10.63M | -8.31M | -7.04M |
Balance Sheet | ||||||
| Total Assets | 14.86M | 8.25M | 13.78M | 10.35M | 12.35M | 21.86M |
| Cash, Cash Equivalents and Short-Term Investments | 6.86M | 1.02M | 6.30M | 1.54M | 8.28M | 12.57M |
| Total Debt | 1.85M | 281.81K | 1.15M | 1.92M | 0.00 | 0.00 |
| Total Liabilities | 6.11M | 5.44M | 5.60M | 6.67M | 5.81M | 6.85M |
| Stockholders Equity | 8.96M | 3.00M | 8.33M | 3.80M | 6.62M | 15.06M |
Cash Flow | ||||||
| Free Cash Flow | -11.44M | -9.91M | -9.79M | -7.88M | -3.74M | -11.30M |
| Operating Cash Flow | -11.10M | -9.68M | -9.57M | -7.38M | -3.36M | -11.30M |
| Investing Cash Flow | -295.29K | -231.84K | -221.43K | -694.14K | -880.22K | 0.00 |
| Financing Cash Flow | 15.54M | 4.60M | 14.56M | 1.44M | 0.00 | 23.40M |
Intelligent Bio Solutions Technical Analysis
Negative
1.03
Price Trends
2.67
Negative
3.66
Negative
6.93
Negative
Market Momentum
-0.16
Positive
38.78
Neutral
9.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Negative. The current price of 1.03 is below the 20-day moving average (MA) of 2.45, below the 50-day MA of 2.67, and below the 200-day MA of 6.93, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 38.78 is Neutral, neither overbought nor oversold. The STOCH value of 9.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBS.
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions disclosed 58 risk factors in its most recent earnings report. Intelligent Bio Solutions reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intelligent Bio Solutions Peers Comparison
UnderperformOutperform
Sector (51)
INBS
Intelligent Bio Solutions
2.29
-16.01
-87.49%
ISPC
iSpecimen
2.59
-31.81
-92.47%
BGLC
BioNexus Gene Lab Corp
2.61
-0.13
-4.74%
BIAF
bioAffinity Technologies, Inc.
0.84
-6.06
-87.87%
Intelligent Bio Solutions Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances Codeine Drug Test Studies
Positive
Jun 16, 2026
On June 16, 2026, Intelligent Bio Solutions Inc. announced it had initiated an Interference Study to support an FDA 510(k) submission seeking U.S. market clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codei...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Launches FDA Study for Codeine Test
Positive
Jun 2, 2026
On June 2, 2026, Intelligent Bio Solutions Inc. announced it had begun a multi-site Method Comparison Study to support an FDA 510(k) submission seeking U.S. clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Intelligent Bio Solutions Updates Investor Presentation and Share Count
Neutral
Apr 20, 2026
On April 20, 2026, Intelligent Bio Solutions Inc. announced that it had made an investor presentation on its business and operations available to shareholders via the investors section of its website, providing the market with formal, regulated ac...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Intelligent Bio Solutions Grants Equity Awards, Updates ATM Capacity
Positive
Mar 23, 2026
On March 18, 2026, Intelligent Bio Solutions granted time- and performance-vesting restricted stock to its directors, officers and employees under its 2019 Long Term Incentive Plan, including sizable awards to its CEO and CFO that vest over four y...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.